Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Hanger, Inc.    HNGR

HANGER, INC.

(HNGR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Hanger : announces findings of newly published study that reveals early receipt of a prosthesis reduces overall healthcare utilization

10/07/2020 | 03:40pm EST

AUSTIN, Texas, Oct. 7, 2020 -Hanger, Inc. (NYSE: HNGR) today announced results of its second IMPACT study, which evaluates the impact of receipt of a prosthesis on overall healthcare utilization. Emergency department use, a common proxy for healthcare utilization, was assessed in the context of timing of receipt of a lower limb prosthesis following amputation, as well as not receiving a prosthesis. The IMPACT 2 study utilized the IBM Watson Truven Health Marketscan, a national commercial claims database, and analyzed data on 510 patients with lower limb amputations.

Results suggest that individuals who received an early prosthesis, within three months following a lower limb amputation, were 48 percent less likely to use the emergency department compared to those who did not receive a prosthesis, which was true across all age groups. Further, the percentage of emergency department use as a measure of overall healthcare utilization appears to have an upward trend as the time from surgery to prosthesis receipt increases. Additionally, individuals who experienced a fall had 2.8 times the odds of emergency department utilization. The findings were published in the peer-reviewed scientific journal PM&R, the Journal of Injury, Function and Rehabilitation.

'The IMPACT 2 study not only underscores the significance of long-term health benefits for the patient, including reduced falls and better quality of life, it also highlights the value of cost savings in healthcare utilization that comes with receipt of a prosthesis early on in the rehabilitation process,' stated James Campbell, PhD, Hanger Chief Clinical Officer. 'This is yet another illustration of the holistic benefits of early prosthetic rehabilitation.'

The collaborative research was conducted by the clinical and scientific affairs department of Hanger Clinic, including Shane R. Wurdeman, PhD, CP, FAAOP and Taavy A. Miller, PhD, CPO, and accompanied by researchers from the University of North Carolina at Charlotte's Department of Public Health. The IMPACT 2 study is an extension of the initial IMPACT study, based on review of the Watson data. The results of the study were published in PM&R and are now available via early release online here:https://onlinelibrary.wiley.com/doi/10.1002/pmrj.12504, and additional information on the study is available on the Hanger Clinic website here: https://hangerclinic.com/blog/published-research/impact-2-the-role-of-earlier-receipt-of-a-lower-limb-prosthesis-on-emergency-department-utilization/.

The IMPACT series is part of a vast collection of landmark research studies already published, or in various stages of publication by Hanger Clinic's Clinical and Scientific Affairs Department, in collaboration with leading researchers, clinicians, and academic institutions. Additional information on previously published research can be found here: https://hangerclinic.com/for-professionals/research-innovation/.

About Hanger, Inc. - Hanger, Inc. (NYSE: HNGR) delivers orthotic and prosthetic (O&P) patient care, and distributes O&P products and rehabilitative solutions to the broader market. Hanger's Patient Care segment is the largest owner and operator of O&P patient care clinics with approximately 800 locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. With nearly 160 years of clinical excellence and innovation, Hanger's vision is to lead the orthotic and prosthetic markets by providing superior patient care, outcomes, services and value. For more information on Hanger, visit www.hanger.com.

###

Krisita Burket, Hanger, Inc.

904-239-4627, kburket@hanger.com

Meghan Williams, Hanger, Inc.

512-777-3701, megwilliams@hanger.com

Disclaimer

Hanger Inc. published this content on 07 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 October 2020 19:39:05 UTC


© Publicnow 2020
All news about HANGER, INC.
11/16HANGER : to Present at Upcoming Investor Conferences
BU
11/15The Best Gadgets, Webcams and Apps to Improve Your Video Calls
DJ
11/10HANGER : NBC Nightly News with Lester Holt Spotlights Veteran Dan Nevins' Journe..
PU
11/10HANGER : November 2020 Investor Presentation
PU
11/09HANGER : NBC Nightly News with Lester Holt to Feature Dan Nevins, a U.S. Army Ve..
PU
11/05HANGER : announces findings of first-of-its-kind study that compares microproces..
PU
11/04HANGER : 3Q Earnings Snapshot
AQ
11/04HANGER, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/04HANGER : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
11/04HANGER : Reports Third Quarter 2020 Financial Results
BU
More news
Financials (USD)
Sales 2020 985 M - -
Net income 2020 7,60 M - -
Net Debt 2020 - - -
P/E ratio 2020 45,1x
Yield 2020 -
Capitalization 893 M 893 M -
Capi. / Sales 2020 0,91x
Capi. / Sales 2021 0,77x
Nbr of Employees 4 800
Free-Float 94,3%
Chart HANGER, INC.
Duration : Period :
Hanger, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANGER, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 22,50 $
Last Close Price 23,43 $
Spread / Highest target -1,84%
Spread / Average Target -3,97%
Spread / Lowest Target -6,10%
EPS Revisions
Managers
NameTitle
Vinit K. Asar President, Chief Executive Officer & Director
Christopher B. Begley Non-Executive Chairman
Thomas E. Kiraly Chief Financial Officer & Executive Vice President
C. Scott Ranson Chief Information Officer & EVP-Corporate Services
James H. Campbell Chief Clinical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
HANGER, INC.-17.49%893
AIER EYE HOSPITAL GROUP CO., LTD.109.10%39 788
FRESENIUS SE & CO. KGAA-24.21%25 191
IHH HEALTHCARE1.28%11 895
BANGKOK DUSIT MEDICAL SERVICES0.00%11 785
RAMSAY HEALTH CARE LIMITED-10.27%10 895